We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

109 hedge funds and large institutions have $1.9B invested in China Biologic Products Holdings, Inc. in 2015 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

320% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 10

50% more funds holding in top 10

Funds holding in top 10: 46 (+2)

40% more funds holding

Funds holding: 78109 (+31)

32% more capital invested

Capital invested by funds: $1.44B → $1.9B (+$465M)

32% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 28

16% more call options, than puts

Call options by funds: $18.8M | Put options by funds: $16.3M

Holders
109
Holders Change
+31
Holders Change %
+39.74%
% of All Funds
2.94%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.16%
New
42
Increased
37
Reduced
28
Closed
10
Calls
$18.8M
Puts
$16.3M
Net Calls
+$2.53M
Net Calls Change
+$7.26M
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Warburg Pincus
New York
$961M -$278M -2,645,000 -24%
Capital World Investors
2
Capital World Investors
California
$117M +$107M +1,019,000 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$111M +$60.6M +576,847 +147%
VAM
4
Visium Asset Management
New York
$57.6M +$6.54M +62,251 +14%
Fidelity International
5
Fidelity International
Bermuda
$52.1M +$9.71M +92,450 +26%
Renaissance Technologies
6
Renaissance Technologies
New York
$36.8M -$3.07M -29,222 -8%
BG
7
BlackRock Group
United Kingdom
$28M +$24.9M +236,549 +3,839%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$26.6M +$19.9M +188,940 +452%
BIT
9
BlackRock Institutional Trust
California
$23.9M +$14M +133,074 +178%
DKCM
10
Davidson Kempner Capital Management
New York
$22.9M +$9.67M +92,000 +86%
KM
11
Kylin Management
New York
$21.7M +$19.8M +188,226 New
MICM
12
Matthews International Capital Management
California
$21.1M -$1.58M -15,000 -8%
Morgan Stanley
13
Morgan Stanley
New York
$18.7M +$1.22M +11,626 +8%
UBS AM
14
UBS AM
Illinois
$18.6M +$17M +161,629 New
BlackRock
15
BlackRock
New York
$18.4M +$16.8M +160,044 New
Ameriprise
16
Ameriprise
Minnesota
$17.3M +$9.88M +94,009 +168%
PA
17
Perceptive Advisors
New York
$17M +$8.15M +77,604 +111%
DCM
18
Discovery Capital Management
Connecticut
$16.1M +$14.7M +140,000 New
ACM
19
Apex Capital Management
Ohio
$15.7M +$1.86M +17,750 +15%
EMR
20
Errol M. Rudman
$15M +$2.1M +20,000 +18%
Principal Financial Group
21
Principal Financial Group
Iowa
$15M +$13.6M +129,869 New
Deutsche Bank
22
Deutsche Bank
Germany
$13.3M +$1.59M +15,128 +15%
CAM
23
Cormorant Asset Management
Massachusetts
$12.8M +$3.68M +35,000 +46%
BIM
24
Bogle Investment Management
Massachusetts
$12.5M +$8.06M +76,700 +242%
William Blair & Company
25
William Blair & Company
Illinois
$12.2M +$2.77M +26,375 +33%

CBPO Hedge Fund Activity: Q2 2015 in Review

109 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2015, worth a combined $1.9B — up 32% from $1.44B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new CBPO positions and 10 closed out — a net gain of 32 holders — while 37 added to existing stakes and 28 trimmed.

The largest buyer was Capital World Investors, opening a new position worth an estimated $107M. The largest seller was Warburg Pincus, cutting an estimated $278M.

  • 109 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2015, up from 78 in Q1 2015.
  • Funds reported $1.9B of China Biologic Products Holdings, Inc. stock for Q2 2015, up 32% quarter-over-quarter.
  • 42 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2015 and 10 closed out, a net change of +32 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q2 2015 was Capital World Investors, an estimated $107M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q2 2015 was Warburg Pincus, an estimated $278M sold.

Based on aggregated 13F filings for Q2 2015.